Chablis Patrick Despain, DC | |
1425 Belle Meade Rd Apt 62, Bells, TN 38006-3675 | |
(713) 540-4776 | |
Not Available |
Full Name | Chablis Patrick Despain |
---|---|
Gender | Female |
Speciality | Chiropractor |
Location | 1425 Belle Meade Rd Apt 62, Bells, Tennessee |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1952665135 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
111N00000X | Chiropractor | DC0000003608 (Tennessee) | Primary |
Mailing Address | Practice Location Address |
---|---|
Chablis Patrick Despain, DC 1425 Belle Meade Rd Apt 62, Bells, TN 38006-3675 Ph: () - | Chablis Patrick Despain, DC 1425 Belle Meade Rd Apt 62, Bells, TN 38006-3675 Ph: (713) 540-4776 |
News Archive
Preliminary research from the Centers for Disease Control and Prevention (CDC) suggests that community acquired pneumonia (CAP) caused by the Staphylococcus aureus bacterium may be more common than originally suspected, including that caused by antibiotic resistant strains.
The American Hospital Association, through its subsidiary, AHA Solutions, Inc., has announced its exclusive endorsement of EXTENSION® HealthID™. HealthID™ is a secure smart card that holds individual patient data for use by the hospitals to improve the care experience. Hospitals are able to quickly find and use patient's information within an individual facility or across their system or network. The benefits of the smart card include providing much improved patient experiences and streamlined administrative costs.
Aeolus Pharmaceuticals, Inc. announced today that after review of the Company's white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.
Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.
Despite their different triggers, the same molecular chain of events appears to be responsible for brain cell death from strokes, injuries and even such neurodegenerative diseases as Alzheimer's.
› Verified 6 days ago